778 related articles for article (PubMed ID: 37842290)
1. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
2. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
3. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
[TBL] [Abstract][Full Text] [Related]
4. Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease.
Colantoni A; Bucci T; Cocomello N; Angelico F; Ettorre E; Pastori D; Lip GYH; Del Ben M; Baratta F
Cardiovasc Diabetol; 2024 May; 23(1):175. PubMed ID: 38769519
[TBL] [Abstract][Full Text] [Related]
5. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
[TBL] [Abstract][Full Text] [Related]
6. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
7. Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type 2 diabetes mellitus.
Sakurai T; Iimuro S; Araki A; Umegaki H; Ohashi Y; Yokono K; Ito H
Gerontology; 2010; 56(2):141-9. PubMed ID: 19828932
[TBL] [Abstract][Full Text] [Related]
8. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
9. Models Predictive of Metabolic Syndrome Components in Obese Pediatric Patients.
Ortega-Cortes R; Trujillo X; Hurtado López EF; López Beltrán AL; Colunga Rodríguez C; Barrera-de Leon JC; Tlacuilo-Parra A
Arch Med Res; 2016 Jan; 47(1):40-8. PubMed ID: 26820798
[TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
[TBL] [Abstract][Full Text] [Related]
11. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
Lake JE; Taron J; Ribaudo HJ; Leon-Cruz J; Utay NS; Swaminathan S; Fitch KV; Kileel EM; Paradis K; Fulda ES; Ho KS; Luetkemeyer AF; Johnston CD; Zanni MV; Douglas PS; Grinspoon SK; Lu MT; Fichtenbaum CJ;
AIDS; 2023 Nov; 37(14):2149-2159. PubMed ID: 37503623
[TBL] [Abstract][Full Text] [Related]
12. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
13. Simple proxies of insulin resistance identify obese metabolic dysfunction-associated fatty liver disease subjects with advanced liver disease.
Petralli G; Salvati A; Tricò D; Ricco G; Colombatto P; Brunetto MR; Solini A
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3736. PubMed ID: 37839068
[TBL] [Abstract][Full Text] [Related]
14. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
[TBL] [Abstract][Full Text] [Related]
15. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study.
Zyśk B; Ostrowska L; Smarkusz-Zarzecka J; Orywal K; Mroczko B; Cwalina U
Nutrients; 2024 May; 16(9):. PubMed ID: 38732626
[TBL] [Abstract][Full Text] [Related]
18. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
[TBL] [Abstract][Full Text] [Related]
20. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]